Nisa Investment Advisors LLC Buys 55,314 Shares of Accolade, Inc. (NASDAQ:ACCD)

Nisa Investment Advisors LLC grew its position in Accolade, Inc. (NASDAQ:ACCD) by 15,113.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 55,680 shares of the company’s stock after acquiring an additional 55,314 shares during the period. Nisa Investment Advisors LLC owned 0.07% of Accolade worth $190,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of ACCD. Mission Creek Capital Partners Inc. bought a new position in shares of Accolade during the third quarter valued at $38,000. Pallas Capital Advisors LLC bought a new stake in shares of Accolade in the fourth quarter worth $38,000. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in Accolade in the third quarter valued at $46,000. Wolverine Trading LLC acquired a new position in Accolade during the 3rd quarter worth about $51,000. Finally, Point72 Asia Singapore Pte. Ltd. grew its position in shares of Accolade by 1,144.1% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company’s stock valued at $81,000 after buying an additional 19,232 shares during the last quarter. Institutional investors and hedge funds own 84.99% of the company’s stock.

Insider Buying and Selling at Accolade

In other news, CEO Rajeev Singh sold 13,357 shares of Accolade stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $3.60, for a total transaction of $48,085.20. Following the completion of the transaction, the chief executive officer now directly owns 814,316 shares in the company, valued at $2,931,537.60. This trade represents a 1.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 41,947 shares of company stock worth $154,439. 8.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ACCD has been the subject of a number of analyst reports. Needham & Company LLC restated a “hold” rating on shares of Accolade in a research report on Wednesday, January 8th. Leerink Partnrs downgraded shares of Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Leerink Partners reaffirmed a “market perform” rating on shares of Accolade in a research note on Wednesday, January 8th. Stephens downgraded shares of Accolade from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Finally, William Blair lowered shares of Accolade from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 8th. Twelve research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $7.55.

Accolade Stock Performance

Shares of ACCD opened at $6.88 on Friday. Accolade, Inc. has a one year low of $3.08 and a one year high of $13.93. The company has a market cap of $561.31 million, a PE ratio of -3.06 and a beta of 2.08. The stock has a 50-day moving average of $4.61 and a 200-day moving average of $4.09. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.63 and a quick ratio of 2.63.

Accolade (NASDAQ:ACCD) last announced its quarterly earnings data on Friday, January 10th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.01. Accolade had a negative return on equity of 20.74% and a negative net margin of 40.36%. On average, equities research analysts predict that Accolade, Inc. will post -1.07 EPS for the current fiscal year.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.